tbuckley/cabot-search huggingface dataset:
Loss of CXCR4 nuclear immunoreactivity in synovial sarcoma (SS) correlates with poor survival
Authors: S. Grisanti, F. Facchetti, A. P. Dei Tos, E. Rossi, L. Ardighieri, V. D. Ferrari, V. Amoroso, L. Bercich, V. Ippolito, G. Marini
Journal: Journal of Clinical Oncology (2007)

10069 Background: The chemokine receptor CXCR4 has been found to be expressed in mesenchymal neoplasms including osteosarcoma, rhabdomyosarcoma, Ewing's sarcoma and SS. Gene products of the HER oncogenic family, such as EGFR and HER2, have been described to be overexpressed in SS and we previously demonstrated coexpression of CXCR4 and EGFR but not HER2 in SS patients. In this study we analysed CXCR4 expression in terms of subcellular localization and extended results to 15 SS patients. Methods: Fifteen SS patients were included in the study. In all cases morphological diagnoses were confirmed molecularly by FISH or RT-PCR specific for t(X;18). HER2 and EGFR expression were determined by immunohistochemistry (IHC) while HER2 gene status was assessed by FISH analysis. CXCR4 expression was determined with an anti-human CXCR4 monoclonal antibody (Clone 44716, R&amp;D Systems, Minneapolis, USA) followed by incubation with the EnVision peroxidase kit (Dakocytomation, Glostrup, Denmark). CXCR4 nuclear vs cytoplasmic expression was correlated with outcome. Results: In all samples IHC analysis for HER2 was negative and no amplification was found by FISH. EGFR expression was observed in 13/15 patients. CXCR4 immunoreactivity was identified in 9/15 cases. CXCR4 and EGFR were coexpressed in 8/15 tumors. Follow-up ranged from 9 to 127 months. After a median follow-up of 39 months, 7 patients were dead of SS, 8 patients were alive (7 of them are disease-free and one has evident disease in the retroperitoneum). All alive and disease-free patients showed nuclear CXCR4 expression whereas 6/7 dead patients expressed cytoplasmic or membrane CXCR4 (p = 0.0008). Conclusions: Loss of nuclear CXCR4 expression is associated with fatal course and may represent a novel prognostic factor. CXCR4 is frequently coexpressed with EGFR but not with HER2. In contrast with previous reports HER2 seems not involved in the carcinogenesis of SS. No significant financial relationships to disclose.
Phase II study of cisplatin and 120-hour continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinoma
Authors: P. Rougier, J.J. Zarba, M. Ducreux, M. Basile, J.P. Pignon, M. Mahjoubi, M. Benahmed, J.P. Droz, E. Cvitkovic, J.P. Armand
Journal: Annals of Oncology (1993)
Early nutritional support and quality of life (QoL): Primary end point in cancer patients during chemo- and/or radiotherapy
Authors: I. Pavese, G. Capuano, M. Di Palma, A. M. Di Palma, F. Satta
Journal: Journal of Clinical Oncology (2005)

8190 Background: progressive weight loss in cancer patients is a complex, multifactorial syndrome occuring through a variety of mechanisms related to the tumor, the host response and cancer treatment. clinical features of malnutrition include anorexia, depletion of lean body mass, muscle weakness, fatigue and impaired immunological function. weight loss significantly correlates with increased chemotherapy-induced toxicity, decreased response to treatment, performance status (PS), survival and QoL. The aim of this study is to evaluate the relationship between QoL and malnutrition in cancer patients who underwent chemo and/or radiotherapy, and the efficacy of an early nutritional support. Methods: between October 2003 and October 2004, 176 cancer patients were enrolled. All patients were evaluated for nutritional status, ECOG PS and QoL (measured with QLQ-C30 v. 3.0) at the biginning of their oncological treatment. Nutritional support consisted in 1,5/2 gr protein and 30 non proteic Kcal/Kg per day, enriched with at least 2 gr of EPA and DHA per os. Patients requiring tube feeding or parenteral nutrition and having major surgical intervention that can influence dietary intake were excluded. Results: Weight loss >10% (range 17 +- 6 SD) was onserved in 51/176 (28,9%) of patients; in 29 patients (59%) before starting treatment, in 8 (15,6%) during treatment, and in 14 (27,4) after treatment. Weight loss was observed more frequently in stomach cancer (88%), pancreatic (66%), head and neck (50%) and colon-rectum (22%). 46/51 patients were evaluable. After 4 weeks of nutritional support, all of the 37/51 (81%) patients who respected the prescribed regimen showed a weight gain of 2,9 +- 1Kg. Weight gain positively correlate with PS (PS0 before treatment: none. PS0 after treatment: 13 (35%) patients) and QoL. Conclusions: Our data suggests that, in cancer patients underling oncological treatment, careful monitoring of nutritional status reduce the incidence of fatigue, ameliorate QoL, allows to complete the full anticancer treatment and improves the outcome. No significant financial relationships to disclose.
A Cell-Based High-Throughput Screen For Novel Inducers Of Fetal Hemoglobin For Treatment Of Sickle Cell Disease, Cooley’s Anemia and β-Thalassemias
Authors: Kenneth R Peterson, Flavia C Costa, Halyna Fedosyuk, Renee Neades, Allen M Chazelle, Lesya Zelenchuk, Andrea H Fonteles, Parmita Dalal, Preston Donover, Melvin Reichman, Anuradha Roy, Rathnam Chaguturu, Li Biaoru, Betty S. Pace
Journal: Blood (2013)
Statin Use Is Associated With Reduced Risk of Colorectal Cancer in Patients With Inflammatory Bowel Diseases
Authors: Ashwin N. Ananthakrishnan, Andrew Cagan, Tianxi Cai, Vivian S. Gainer, Stanley Y. Shaw, Susanne Churchill, Elizabeth W. Karlson, Shawn N. Murphy, Katherine P. Liao, Isaac Kohane
Journal: Clinical Gastroenterology and Hepatology (2016)
Comparison between the three oxaliplatin-based regimens with bevacizumab in patients with metastatic colorectal cancer.
Authors: Yoshihito Ohhara, Mitsukuni Suenaga, Satoshi Matsusaka, Eiji Shinozaki, Nobuyuki Mizunuma, Toshiharu Yamaguchi, Kiyohiko Hatake
Journal: Journal of Clinical Oncology (2012)

687 Background: XELOX (capecitabine/L-OHP) therapy that includes orally administered ﬂuoropyrimidine instead of infusional fluorouracil (5-FU) was approved for metastatic colorectal cancer (mCRC) in Sep 2009 in Japan. A pivotal trial (NO16966 study) demonstrated the non-inferiority of XELOX to FOLFOX (5-FU/L-OHP/LV) and the superiority of those L-OHP-based regimens plus bevacizumab (BV) to those without in the first-line treatment of mCRC. We evaluated the safety and efficacy of XELO+BV compared with FOLFOX4 or mFOLFOX6 plus BV in the first-line treatment for mCRC patients at a single institute. Methods: Between Jun 2007 and Nov 2008, 85 patients received FOLFOX4+BV (FF4 arm), between Dec 2008 and Sep 2009, 40 patients received mFOLFOX6+BV (FF6 arm), and between Oct 2009 and Sep 2010, 60 patients received XELOX+BV (XELOX arm). The best overall responses were evaluated using RECIST 1.0 during chemotherapeutic treatment, and adverse events were graded according to CTCAE ver.3.0. Progression-free survival (PFS) was estimated by Kaplan-Meier methods. Results: Characteristics of patients of FF4 arm, FF6 arm, and XELOX arm were below: median age, 60 yr vs. 62 yr vs. 60.5 yr; gender (male), 48.2 % vs. 62.5 % vs. 58.3%. The overall response rates (CR+PR) were 61.1 %, 72.5 %, and 75 % (95% CI; 50.6-71.8%, 58.0-87.0%, and 63.7-86.3%). Median PFS were 17.0 months, 15.5 months, and 14.4 months, respectively (cut-off: Aug 31, 2011). There were no statistical significances not only between FF4 arm and FF6 arm (log-rank; p=0.641), but also between XELOX arm and FF4+FF6 (FOLFOX) arm (log-rank; p=0.138). FOLFOX arm was associated with higher incidence of grade 3/4 neutropenia than XELOX arm. Grade3 diarrhea and hand-foot syndrome (HFS) were more frequent in XELOX arm. Conclusions: This study suggests that XELOX arm was equal to FOLFOX arm, regardless of regimen, in tumor response and PFS. Further follow-up is necessary to confirm the benefit on survival.
Radioactive microspheres in liver metastases from neuroendocrine cancer (NETLM)
Authors: J. King, D. Glenn, R. Quinn, J. Janssen, W. Liauw, D. L. Morris
Journal: Journal of Clinical Oncology (2008)

15541 Background: There are limited effective treatment options available for patients with unresectable (NETLM). The study aimed to prospectively assess the safety and efficacy of yttrium90 resin microspheres (SIR-Spheres) treatment (SIRT) in unresectable NETLM. Method: Yyttrium90 micro-spheres were administered via a temporarily placed percutaneous hepatic artery catheter to 34 patients with inoperable (NETLM) plus a concomitant 7day systemic infusion of 225mg/m2 5- flurouracil. Response to treatment was measured by three monthly CT imaging and Chromogranin A (CgA) tumor marker. Results: 34 four patients (22 males), mean age 61 years (range 32–79) with inoperable NETLM were treated from December 2003 to December 2005. Mean follow-up was 33.2 months (95% CI 29.9 - 36.7). Site of primary NET was: 1 bronchus; 2 medullary thyroid; 15 gastro-intestinal; 8 pancreas and 8 unknown origin. Tumors were classified as:1vipoma 1 somatostatinoma; 2 glucagonoma; 3 large cell; 23 carcinoid and 2 of unknown origin. Complications post-SIRT included: abdominal pain, mild to severe; nausea and fever and lethargy from one week to one month. Three patients developed biopsy-proven radiation gastritis or ulcer and there was one early death from liver dysfunction. Symptomatic response was seen in 55% of patients. Radiological liver response was seen in 50% of patients, 6 CR (18%) and 11 PR (32%) with median overall survival of 24.4 months (95%CI 18.4 - 30.4). There was a post baseline CgA fall in 19 (26%) at one month; 19 (41%) at 3 months; 15 (43%) at 6 months; 11 (42%) at 12 months; 8 (38%) at 24 months and 3 (46%) at 30 months. Conclusion: An open study of 34 patients demonstrated that radioembolization with resin radioactive microspheres can achieve relatively long term responses in some patients with unresectable neuroendocrine liver metastases. No significant financial relationships to disclose.
90-day mortality rate in cancer patients treated within the context of phase I trials: Can we identify patients who should not go on trial?
Authors: J. Ang, H. Arkenau, D. Olmos, J. Barriuso, S. Ashley, A. Little, S. Pacey, J. S. De Bono, I. Judson, S. B. Kaye
Journal: Journal of Clinical Oncology (2008)

2510 Background: Phase I trials are crucial for the development of new anticancer therapies. Common inclusion criteria for phase I trials include “life expectancy > 3 months”; however, many recently published trials report 90-days mortality rates of more than 20%. Therefore, in this retrospective study, we examined factors that could aid the identification of patients who have a very limited prognosis and thus are not suitable phase I trial candidates. Methods: We identified 97 patients who died within the first 90-days of treatment out of a total of 654 consecutively treated phase I patients, from June 2003 to June 2007. This cohort was compared to a control group with similar baseline characteristics, comprising 215 patients who lived >90 days on phase I studies and were treated from January 2005 to June 2006. In addition, we applied a prognostic score, which was derived from the latter group and based on parameters associated with poor OS (albumin [<35 g/l], LDH >UNL, and >2 sites of metastasis) (Arkenau et al, Proc AACR-NCI-EORTC 2007). Results: Both cohorts received a median of 3 previous treatments (range 0–9) and the male:female ratio was similar (2:1). In keeping with our recently reported survival risk score for phase I patients we demonstrated that patients who died within the first 90 days had a significantly higher risk score in comparison to our control group (score 0: 1% vs 20%; 1: 13% vs 41%; 2: 40% vs 30%; 3: 45% vs 9%), p<0.1*10-9. Furthermore, the multivariate analysis indicated that patients who died during first 90 days presented with a younger median age (55.5 vs 59.1 yrs, p=0.024), increased white blood cell counts (WBC: 8.5 vs 6.8 x109/ml, p=0.028) and poorer ECOG performance status (PS 1: 77 vs 62%; PS 2: 17 vs 6%; p=0.012). Conclusions: This analysis showed that 86% of patients who died during the first 90 days had an increased risk score of 2/3 compared to 39% in the control group. In patients with a risk score of 2/3 the use of variables such as age, WBC and PS may additionally help in selecting appropriate candidates for phase I trial entry. No significant financial relationships to disclose.
Evaluation of the prognostic value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy (DSAC)
Authors: D. Skarlos, H. Gogas, V. Kiriakou, A. Margariti, E. Kirkou, K. Pavlaki, A. Asimaki, T. Toliou, D. Tziortziotis, C. Vamvouka, G. Fountzilas
Journal: Journal of Clinical Oncology (2005)

627 Background: To assess the prognostic significance of positive p53 and Bcl-2 expression in high-risk patients with breast cancer treated with DSAC. Methods: From 11–6-1997 until 2–11-2000, 595 eligible patients were randomized to receive DSAC with epirubicin and intensified CMF with or without paclitaxel. In 397 patients, p53 and Bcl-2 were assessed centrally by immunohistochemistry (IHC) using NeXes automated system (Ventana). Both P53 and Bcl-2 data were available in 375 patients. Results: p53 and Bcl-2 expression was detected in 100 (25.5%) and 194 (49%) patients, respectively. The absence of Bcl-2 expression was significantly higher in patients with p53 expression (p=0.04). Incidence of p53 immuno-positivity was significantly higher in patients with grade III tumors (p<0.001) or negative hormonal receptor (HR) status (p<0.001). The rate of disease progression and death was significantly higher among patients with p53 expression (p=0.004 and p=0.006 respectively). Additionally, negative HR status, was more often recorded among patients with absence of Bcl-2 expression (p=0.002). After adjustment was made for treatment group, patients with absence of Bcl-2 expression and p53 expression had a significantly increased risk of both disease recurrence and death. Conclusions:p53 immuno-positivity was significantly associated with poor prognostic factors and higher incidence of disease relapse and death in patients with breast cancer treated with dose-dense sequential adjuvant chemotherapy. Absence of Bcl-2 expression was related only with negative HR status. No significant financial relationships to disclose.
THE MENACE OF THE HOMICIDAL DEFECTIVE
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Impact of lenalidomide therapy on stem cell mobilization in myeloma
Authors: H. Paripati, A. K. Stewart, R. Fonseca, A. C. Dueck, J. L. Slack, C. B. Reeder, J. Leis, P. L. Bergsagel, A. S. Torloni
Journal: Journal of Clinical Oncology (2008)

8543 Background: Lenalidomide (len) with dexamethasone (dex) is increasingly used as induction therapy in newly diagnosed myeloma patients prior to transplant. We performed a retrospective chart review after the clinical observation of difficulty mobilizing stem cells in patients treated with len/dex was made. Methods: Patients with multiple myeloma (MM) undergoing stem cell collection between January 2005 and October 2007 were analyzed for type and duration of induction therapy, collection efficacy and engraftment in patients who went to transplant. 61 patients were identified, of whom 20 received induction therapy with len/dex, and 41 received other induction therapies. The selected criteria for failure of first and total stem cell collection were defined as: 1. Collection not attempted as peripheral blood CD34+ cell count consistently < 10 cells/microliter; 2. Total CD34+ cells collected < 2 x 106 CD34+ cells/kg body weight. Results: In the len/dex group, stem cell collection was unsuccessful in 9 of 20 (45%) patients on first attempt, compared with 3 of 41(7.3%) patients (p=0.001) treated with alternate regimens. The mean peripheral blood CD34+ counts (14.0 versus 28.9 cells/microliter; p=0.0002) and mean total stem cells collected (5.1 x 106 cells/kg vs 7.4 x 106 cells/kg; p=0.0025) were also significantly lower in the len/dex group versus other induction therapies. Conclusions: These findings have implications for the management of patients with MM proceeding to autologous stem cell transplant. Given the relative inefficiency of stem cell mobilization after len/dex based induction therapy, other strategies for mobilization of stem cells following lenalidomide induction should be considered. Lenalidomide-Based Induction Lenalidomide- Based Induction (N = 20) Other Induction Therapy (N = 41) p values <5 cycles (N = 9) 5 - 9 cycles (N = 8) ≥10 cycles (N = 3) p values Failure of first collection or less than 2 x 106 CD34+ cells/kg 3 (33.3%) 3 (37.5%) 3 (100%) 0.11 9 (45%) 3 (7.3%) 0.0011 Failure of first collection or less than 5 x 106 CD34+ cells / kg * 4 (44%) 6 (75%) 3 (100%) 0.16 13 (65%) 10 (24.4%) 0.0042 Total CD34+ cells collected (mean x 106/kg) 5.5 5.0 3.2 0.39 5.1 7.4 0.0025 Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Celgene, Halozyme, Millennium Celgene, Millennium Millennium, Pfizer
Randomized phase II study of concomitant chemoradiotherapy with 5-fluorouracil-hydroxyurea (FHX) compared to FHX and bevazicumab (BFHX) in intermediate stage head and neck cancer (HNC)
Authors: N. W. Choong, D. J. Haraf, E. E. Cohen, K. M. Stenson, E. A. Blair, A. Dekker, R. Williams, T. G. Karrison, E. E. Vokes
Journal: Journal of Clinical Oncology (2007)

6034 Background: Preclinical data supports inhibition of vascular endothelial growth factor (VEGF) to improve tumor radiosensitivity. Phase I data demonstates that BFHX was tolerable in HNC (Seiwert, pASCO2006). Here we present preliminary toxicity data from a randomized phase II trial in pts with PS 0–2, stage II-IV (T 2–4 N 0–1 M 0 ) HNC. Methods: Pts were randomized (2:1) to receive either BFHX or FHX. Planned sample size is 72pts. Chemotherapy consists of 5- FU (600 mg/m 2 /day continuous infusion for 120 hrs), hydroxyurea (500 mg PO q12 hours for 11 doses) with or without bevacizumab (10 mg/kg IV on day 1), concurrently with twice daily RT on a week on-week off schedule. Results: 21pts (BFHX 14pt and FHX 7pt) have completed therapy and are evaluable for toxicity. Pt characteristics in the BFHX and FHX arms are: median age 61 vs. 55 yrs, males 78% vs. 85%, stage II-III 57% vs. 86% and IV 43% vs. 14%. All pts have PS 0–1. 20 pts are evaluable for toxicity. Two episodes of gr3 leukopenia and one episode of gr 3 neutropenia were observed in the BFHX arm; whereas no gr3 hematologic toxicities were seen in the FHX arm. Mucositis (Gr3 - BFHX 85% vs. FHX 86%) and dermatitis (Gr3 - 0% vs. 14%) were observed in every pt. Other common non- hematologic toxicities were pain (100% vs. 86%), fatigue (77% vs. 86%) and anorexia (62% vs. 51%). No hemorrhagic events were observed. In the BFHX arm, one episode of deep venous thrombosis and one non-neutropenic death from sepsis were observed. Pathologic complete response rates were 92% and 100% in the BFHX and FHX arms, respectively. Conclusions: Preliminary results support the tolerability of BFHX. Toxicity appears to be similar to FHX with an apparent increase in leukopenia consistent with prior reports. Bleeding complications were not increased with BFHX. No significant financial relationships to disclose.
Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia
Authors: Tamara P. Miller, Yimei Li, Marko Kavcic, Andrea B. Troxel, Yuan-Shun V. Huang, Lillian Sung, Todd A. Alonzo, Robert Gerbing, Matt Hall, Marla H. Daves, Terzah M. Horton, Michael A. Pulsipher, Jessica A. Pollard, Rochelle Bagatell, Alix E. Seif, Brian T. Fisher, Selina Luger, Alan S. Gamis, Peter C. Adamson, Richard Aplenc
Journal: Journal of Clinical Oncology (2016)

Reporting of adverse events (AEs) in clinical trials is critical to understanding treatment safety, but data on AE accuracy are limited. This study sought to determine the accuracy of AE reporting for pediatric acute myeloid leukemia clinical trials and to test whether an external electronic data source can improve reporting.
Human Cytomegalovirus and Herpes Simplex Type 2 Virus in Normal and Adenocarcinomatous Prostate Glands&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: I Boldogh, J F Baskar, E C Mar, E S Huang
Journal: JNCI Journal of the National Cancer Institute (1983)

Normal prostate, benign prostate hypertrophy (BHP), and prostate adenocarcinoma (ACP) biopsy specimens were analyzed for the presence of human cytomegalovirus (HCMV) and herpes simplex virus type 2 (HSV-2)-specific macromolecules. HCMV DNA homologous sequences were detected in 2 of 13 normal prostate, 2 of 9 BHP, and 3 of 10 ACP tissues, and HSV-2 DNA homologous sequences were found in 1 normal prostate tissue and 2 ACP tissues. In situ DNA-RNA hybridizations indicated HCMV-specific RNA in 3 of 8 BHP and 4 of 9 ACP tissues. No positive in situ hybridization for HCMV RNA was observed in normal prostate tissues. Parallel in situ DNA-RNA hybridization localized HSV-2-specific RNA in only 1 of 8 tumor sections. No HSV-2-specific RNA was observed in sections of normal and BHP tissues. Anticomplement immunofluorescence (ACIF) tests of BHP and ACP specimens showed specific HCMV immunofluorescence in 3 of 8 BHP and 4 of 9 ACP tissues. ACIF results correlate closely with in situ hybridization results and imply some degree of HCMV association with prostatic abnormality. The results also suggest that latent HCMV may be harbored by the human prostate gland.